BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Glaspy JA, Lim-Watson MZ, Libre MA, Karkare SS, Hadker N, Bajic-Lucas A, Strauss WE, Dahl NV. Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review. Ther Clin Risk Manag 2020;16:245-59. [PMID: 32308402 DOI: 10.2147/TCRM.S243462] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Auerbach M, Achebe MM, Thomsen LL, Derman RJ. Efficacy and safety of ferric derisomaltose (FDI) compared with iron sucrose (IS) in patients with iron deficiency anemia after bariatric surgery. Obes Surg 2022. [PMID: 35000068 DOI: 10.1007/s11695-021-05858-0] [Reference Citation Analysis]
2 Kassianides X, Bhandari S. Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review. Drugs Context 2021;10:2020-11-3. [PMID: 33519940 DOI: 10.7573/dic.2020-11-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
3 Glaspy JA, Wolf M, Strauss WE. Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome. Adv Ther 2021;38:3531-49. [PMID: 34053011 DOI: 10.1007/s12325-021-01770-2] [Reference Citation Analysis]
4 Callejas-Moraga EL, Casado E, Gomez-Nuñez M, Caresia-Aroztegui AP. Severe osteomalacia with multiple insufficiency fractures secondary to intravenous iron therapy in a patient with Rendu-Osler-Weber syndrome. Bone Rep 2020;13:100712. [PMID: 32923530 DOI: 10.1016/j.bonr.2020.100712] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Rosano G, Schiefke I, Göhring UM, Fabien V, Bonassi S, Stein J. A Pooled Analysis of Serum Phosphate Measurements and Potential Hypophosphataemia Events in 45 Interventional Trials with Ferric Carboxymaltose. J Clin Med 2020;9:E3587. [PMID: 33172157 DOI: 10.3390/jcm9113587] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Bazeley JW, Wish JB. Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review. Am J Kidney Dis 2021:S0272-6386(21)00955-0. [PMID: 34758368 DOI: 10.1053/j.ajkd.2021.09.017] [Reference Citation Analysis]
7 Ghelichi-Ghojogh M, Fararouei M, Seif M, Shahryari B, Pakfetrat M. Impact of social and clinical factors on the diagnostic delay of chronic kidney disease: an evaluation study. Int Urol Nephrol 2021. [PMID: 34713367 DOI: 10.1007/s11255-021-03037-9] [Reference Citation Analysis]
8 Aljuraibah F, Bacchetta J, Brandi ML, Florenzano P, Javaid MK, Mäkitie O, Raimann A, Rodriguez M, Siggelkow H, Tiosano D, Vervloet M, Wagner CA. An Expert Perspective on Phosphate Dysregulation With a Focus on Chronic Hypophosphatemia. J Bone Miner Res 2021. [PMID: 34870347 DOI: 10.1002/jbmr.4486] [Reference Citation Analysis]
9 Adhikari S, Mamlouk O, Rondon-Berrios H, Workeneh BT. Hypophosphatemia in cancer patients. Clin Kidney J 2021;14:2304-15. [PMID: 34754427 DOI: 10.1093/ckj/sfab078] [Reference Citation Analysis]
10 Schaefer B, Tobiasch M, Wagner S, Glodny B, Tilg H, Wolf M, Zoller H. Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management. Bone 2021;154:116202. [PMID: 34534708 DOI: 10.1016/j.bone.2021.116202] [Reference Citation Analysis]
11 Richards T, Breymann C, Brookes MJ, Lindgren S, Macdougall IC, McMahon LP, Munro MG, Nemeth E, Rosano GMC, Schiefke I, Weiss G. Questions and answers on iron deficiency treatment selection and the use of intravenous iron in routine clinical practice. Ann Med 2021;53:274-85. [PMID: 33426933 DOI: 10.1080/07853890.2020.1867323] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]